MAM
SRPT icon

Meeder Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Meeder Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1K Buy
+1,507
New +$28.5K ﹤0.01% 552
2025
Q2 		– Sell
-26
Closed -$1.66K – 1000
2025
Q1 		$1.66K Sell
26
-6
-19% -$632 ﹤0.01% 876
2024
Q4 		$3.89K Sell
32
-514
-94% -$63K ﹤0.01% 859
2024
Q3 		$68.2K Buy
546
+21
+4% +$2.9K ﹤0.01% 328
2024
Q2 		$83K Buy
525
+492
+1,491% +$63.2K 0.01% 278
2024
Q1 		$4.27K Buy
+33
New +$4.04K ﹤0.01% 650
2022
Q3 		– Sell
-4
Closed – – 2359
2022
Q2 		$0 Sell
4
-22
-85% -$1.62K ﹤0.01% 2418
2022
Q1 		$2K Buy
+26
New +$1.99K ﹤0.01% 2080
2021
Q4 		– Sell
-14
Closed -$1K – 2185
2021
Q3 		$1K Sell
14
-4
-22% -$308 ﹤0.01% 2372
2021
Q2 		$1K Sell
18
-1
-5% -$76 ﹤0.01% 2392
2021
Q1 		$1K Sell
19
-17
-47% -$1.57K ﹤0.01% 2263
2020
Q4 		$6K Buy
36
+1
+3% +$148 ﹤0.01% 1174
2020
Q3 		$5K Sell
35
-7
-17% -$1.06K ﹤0.01% 1593
2020
Q2 		$7K Sell
42
-25
-37% -$3.4K ﹤0.01% 1437
2020
Q1 		$7K Sell
67
-5
-7% -$572 ﹤0.01% 1671
2019
Q4 		$9K Buy
72
+45
+167% +$4.54K ﹤0.01% 1597
2019
Q3 		$2K Sell
27
-202
-88% -$23.9K ﹤0.01% 1984
2019
Q2 		$35K Sell
229
-4,980
-96% -$605K ﹤0.01% 1055
2019
Q1 		$620K Buy
5,209
+2,644
+103% +$340K 0.05% 343
2018
Q4 		$281K Buy
2,565
+2,416
+1,621% +$302K 0.03% 430
2018
Q3 		$24K Sell
149
-272
-65% -$37.2K ﹤0.01% 984
2018
Q2 		$55.6K Buy
+421
New +$39.7K ﹤0.01% 731
2018
Q1 		– Sell
-30
Closed -$2K – 1732
2017
Q4 		$2K Sell
30
-44
-59% -$2.33K ﹤0.01% 1505
2017
Q3 		$3K Buy
+74
New +$2.96K ﹤0.01% 1386
2017
Q2 		– Sell
-103
Closed -$3K – 1852
2017
Q1 		$3K Buy
+103
New +$3.19K ﹤0.01% 1280

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Meeder Asset Management's SRPT Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 1,507 shares worth $27.1K. The stake represents ﹤0.01% of the portfolio and ranks #552 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in SRPT as recently as Q1 2025.

Meeder Asset Management first reported a position in SRPT in Q1 2017 and has held it in 25 quarters since. The position peaked at $620K in Q1 2019. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Meeder Asset Management held 1,507 shares of Sarepta Therapeutics worth $27.1K as of Q2 2026.
  • Sarepta Therapeutics was a new Meeder Asset Management position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #552 holding.
  • Meeder Asset Management first reported a position in Sarepta Therapeutics in Q1 2017 and has held it in 25 quarters since.
  • Meeder Asset Management's Sarepta Therapeutics position peaked at $620K in Q1 2019.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.